locally advanced pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Ability to comply with the study protocol and provide written informed consent; 2. Aged between 18 and 80 years; 3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); 4. Defined as locally advanced unresectable diseases according to the NCCN Guidelines Pancreatic Adenocarcinoma Guidelines (Version 2.2025); 5. No evidence of distant metastasis based on imaging examinations; 6. The primary lesion or positive lymph nodes do not invade the gastrointestinal tract; 7. ECOG performance status score of 0–1; 8. Adequate bone marrow, as well as hepatic and renal function;
Exclusion criteria
Exclusion criteria: 1. Tumor invaded adjacent gastrointestinal structures; 2. History of prior radiotherapy to the upper abdomen or radioactive seed implantation that may lead to overlapping radiation fields; 3. Previous local therapies for pancreatic cancer such as high-intensity focused ultrasound or irreversible electroporation, etc. 4. Presence of internal implanted that may malfunction under high-energy radiation exposure or interfere with radiation dose distribution; 5. Unable to lie prone for more than 15 minutes on the immobilization device; 6. Prior chemotherapy regimen not including gemcitabine or fluoropyrimidines; 7. Presence of active gastric and/or duodenal ulcers, active upper abdominal infections, active inflammatory bowel disease, or other severe comorbidities; 8. History of other malignancies;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Acute toxicity; | — |
Countries
China
Contacts
The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center